84 related articles for article (PubMed ID: 17091486)
1. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
[TBL] [Abstract][Full Text] [Related]
2. Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy.
Pretz JL; Barysauskas CM; George S; Hornick JL; Raut CP; Chen YE; Marcus KJ; Choy E; Hornicek F; Ready JE; DeLaney TF; Baldini EH
Oncologist; 2017 Oct; 22(10):1265-1270. PubMed ID: 28550026
[TBL] [Abstract][Full Text] [Related]
3. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
Anderton J; Moroz V; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Kaiser S; Fernández-Pinto M; Fenwick N; Evans A; Strauss S; Whelan J; Wheatley K; Brennan B
Trials; 2020 Jan; 21(1):96. PubMed ID: 31952545
[TBL] [Abstract][Full Text] [Related]
4. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
Wolden SL; Lyden ER; Arndt CA; Hawkins DS; Anderson JR; Rodeberg DA; Morris CD; Donaldson SS
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1071-6. PubMed ID: 26581144
[TBL] [Abstract][Full Text] [Related]
5. Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy.
Bisogno G; Fuchs J; Dasgupta R; Ferrari A; Haduong JH; Rogers T; Walterhouse DO; Coppadoro B; Xue W; Vokuhl C; Hawkins DS; Seitz G; Merks JHM; Sparber-Sauer M; Venkatramani R
Cancer; 2022 Dec; 128(23):4150-4156. PubMed ID: 36250420
[TBL] [Abstract][Full Text] [Related]
6. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.
DuBois SG; Krailo MD; Glade-Bender J; Buxton A; Laack N; Randall RL; Chen HX; Seibel NL; Boron M; Terezakis S; Hill-Kayser C; Hayes A; Reid JM; Teot L; Rakheja D; Womer R; Arndt C; Lessnick SL; Crompton BD; Kolb EA; Daldrup-Link H; Eutsler E; Reed DR; Janeway KA; Gorlick RG
J Clin Oncol; 2023 Apr; 41(11):2098-2107. PubMed ID: 36669140
[TBL] [Abstract][Full Text] [Related]
7. Metastatic Rhabdomyosarcoma: Results of the European
Schoot RA; Chisholm JC; Casanova M; Minard-Colin V; Geoerger B; Cameron AL; Coppadoro B; Zanetti I; Orbach D; Kelsey A; Rogers T; Guizani C; Elze M; Ben-Arush M; McHugh K; van Rijn RR; Ferman S; Gallego S; Ferrari A; Jenney M; Bisogno G; Merks JHM
J Clin Oncol; 2022 Nov; 40(32):3730-3740. PubMed ID: 35709412
[TBL] [Abstract][Full Text] [Related]
8. Age-related toxicity in patients with rhabdomyosarcoma: a report from the children's oncology group.
Altaf S; Enders F; Lyden E; Donaldson SS; Rodeberg D; Arndt C
J Pediatr Hematol Oncol; 2014 Nov; 36(8):599-604. PubMed ID: 24936741
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of combining temsirolimus to vincristine, dactinomycin, cyclophosphamide, and vincristine and irinotecan chemotherapy for children with intermediate-risk rhabdomyosarcoma: A report from Children's Oncology Group.
Oberoi S; Qumseya A; Xue W; Harrison DJ; Rudzinski ER; Wolden SL; Dasgupta R; Venkatramani R; Gupta AA
Pediatr Blood Cancer; 2023 May; ():e30436. PubMed ID: 37243336
[TBL] [Abstract][Full Text] [Related]
10. Local Treatment of Children Suffering From Parameningeal Rhabdomyosarcoma: A Retrospective Single-Center Study From China.
Peng X; Xiong X; Li Y; Li C; Wang Z; Wu Y; Su M; Weng W; Huang K; Zhou D; Fang J
Cancer Control; 2024; 31():10732748241240655. PubMed ID: 38514935
[TBL] [Abstract][Full Text] [Related]
11. What are the Optimal Systemic Treatment Options for Rhabdomyosarcoma?
Miwa S; Hayashi K; Taniguchi Y; Asano Y; Demura S
Curr Treat Options Oncol; 2024 May; ():. PubMed ID: 38750399
[TBL] [Abstract][Full Text] [Related]
12. An unusual presentation of neonatal rhabdomyosarcoma: a case report.
Strah D; Stanley K; Oatmen K; Kylat RI; Dishop M; de la Maza M
Front Pediatr; 2023; 11():1233334. PubMed ID: 37964815
[TBL] [Abstract][Full Text] [Related]
13. Insights into pediatric rhabdomyosarcoma research: Challenges and goals.
Yohe ME; Heske CM; Stewart E; Adamson PC; Ahmed N; Antonescu CR; Chen E; Collins N; Ehrlich A; Galindo RL; Gryder BE; Hahn H; Hammond S; Hatley ME; Hawkins DS; Hayes MN; Hayes-Jordan A; Helman LJ; Hettmer S; Ignatius MS; Keller C; Khan J; Kirsch DG; Linardic CM; Lupo PJ; Rota R; Shern JF; Shipley J; Sindiri S; Tapscott SJ; Vakoc CR; Wexler LH; Langenau DM
Pediatr Blood Cancer; 2019 Oct; 66(10):e27869. PubMed ID: 31222885
[TBL] [Abstract][Full Text] [Related]
14. The Capacity of Drug-Metabolising Enzymes in Modulating the Therapeutic Efficacy of Drugs to Treat Rhabdomyosarcoma.
Picher EA; Wahajuddin M; Barth S; Chisholm J; Shipley J; Pors K
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473371
[TBL] [Abstract][Full Text] [Related]
15. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
[TBL] [Abstract][Full Text] [Related]
16. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
[TBL] [Abstract][Full Text] [Related]
17. The Third Intergroup Rhabdomyosarcoma Study.
Crist W; Gehan EA; Ragab AH; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J; Heyn R
J Clin Oncol; 1995 Mar; 13(3):610-30. PubMed ID: 7884423
[TBL] [Abstract][Full Text] [Related]
18. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
[TBL] [Abstract][Full Text] [Related]
19. Treatment of adult rhabdomyosarcoma.
Ogilvie CM; Crawford EA; Slotcavage RL; King JJ; Lackman RD; Hartner L; Staddon AP
Am J Clin Oncol; 2010 Apr; 33(2):128-31. PubMed ID: 19770626
[TBL] [Abstract][Full Text] [Related]
20. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Raney RB; Walterhouse DO; Meza JL; Andrassy RJ; Breneman JC; Crist WM; Maurer HM; Meyer WH; Parham DM; Anderson JR
J Clin Oncol; 2011 Apr; 29(10):1312-8. PubMed ID: 21357783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
